Drugs / Enzelkitug
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05581004 | Oct 2022 → Jul 2028 expected | cervical cancer, clear cell renal carcinoma, colorectal cancer, esophageal cancer +7 | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enzelkitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05581004 ↗ |
| Route | Intravenous | “as an intravenous (IV) infusion” NCT05581004 ↗ |